Teladoc (TDOC) closed at $10.11, up +1.1% from the prior day, outperforming the S&P 500. However, the stock has dropped by 21.45% in the past month, falling short of the Medical sector and S&P 500 gains.

Teladoc’s upcoming earnings report projects an EPS of -$0.35, a 12.5% increase from last year. Revenue is estimated at $649.84 million, down 0.39% from the previous year. Analysts suggest positive estimate revisions can impact the company’s stock price momentum.

The Medical Services industry, part of the Medical sector, holds a Zacks Industry Rank of 97, placing it within the top 39% of industries. Zacks recommends monitoring stock-moving metrics on Zacks.com for valuable insights.

Zacks highlights the growing demand for clean hydrogen energy, projecting a $500 billion market by 2030. 3 hydrogen stocks are identified for potential growth, with one boasting a +2,400% return over 25 years and another securing $15 billion in capital commitments for low carbon hydrogen products through 2027.

For further details and stock analysis, visit Zacks.com.

Read more at Nasdaq: Teladoc (TDOC) Outpaces Stock Market Gains: What You Should Know